Mesoblast Limited (MESO) vs Urogen Pharma (URGN)
- Mesoblast Limited MESO 13.28 −4.80%
- Urogen Pharma URGN 34.56 −5.60%
Mesoblast Limited and Urogen Pharma are both Biotechnology companies. Mesoblast Limited and Urogen Pharma are of similar size ($1.8B and $1.8B). Urogen Pharma grew revenue faster over the last twelve months: 100.3% against −26.5%. Urogen Pharma has the higher net margin (−51.7% vs −1,091.7%) and the higher return on invested capital (0.00% vs 0.00%). Across the 16 metrics below, Urogen Pharma leads on 10 and Mesoblast Limited on 6.
Valuation
Profitability
| Metric | MESO | URGN | Biotechnology median |
|---|---|---|---|
| Gross margin | (269.72%) | 90.85% | 65.16% |
| Operating margin | (826.28%) | (35.32%) | 0.00% |
| Net margin | (1,091.71%) | (51.73%) | 0.00% |
| Free cash flow margin | 0.00% | (84.32%) | 0.00% |
| Return on equity | 0.00% | 86.49% | (56.36%) |
| Return on assets | 0.00% | (42.33%) | (48.04%) |
| Return on invested capital | 0.00% | 0.00% | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack